---
title: "FDA approves Eisai, Biogen’s Leqembi Iqlik subcutaneous initiation dose for early Alzheimer’s disease"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292534418.md"
description: "The FDA has approved the LEQEMBI IQLIK subcutaneous initiation dose for early Alzheimer's disease, developed by Eisai and co-commercialized with Biogen. This approval allows patients to begin treatment using an at-home autoinjector once weekly, replacing the need for IV infusions. The US launch is scheduled for late August 2026."
datetime: "2026-07-13T21:37:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292534418.md)
  - [en](https://longbridge.com/en/news/292534418.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292534418.md)
---

# FDA approves Eisai, Biogen’s Leqembi Iqlik subcutaneous initiation dose for early Alzheimer’s disease

-   FDA cleared Eisai’s once-weekly LEQEMBI IQLIK subcutaneous injection as an initiation dose for early Alzheimer’s disease. \* US launch planned for late August 2026; patients can start on at-home autoinjector dosing instead of IV infusions. \* Biogen co-commercializes lecanemab with Eisai. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eisai Co. Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607131736PR\_NEWS\_USPR\_\_\_\_\_AQ03522) on July 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [BIIB.US](https://longbridge.com/en/quote/BIIB.US.md)
- [4523.JP](https://longbridge.com/en/quote/4523.JP.md)

## Related News & Research

- [How Investors May Respond To Eisai (TSE:4523) Advancing Lecanemab Data And New CNS Oncology Filings](https://longbridge.com/en/news/292407767.md)
- [Why Is Biogen Stock Falling Tuesday?](https://longbridge.com/en/news/292652224.md)
- [19:03 ETADDF Statement: FDA Approval of Subcutaneous Starting Dose for Leqembi Advances Alzheimer's Care Toward Combination Therapy Future](https://longbridge.com/en/news/292539150.md)
- [Biogen posts AAIC 2026 presentation on Alzheimer’s drug diranersen](https://longbridge.com/en/news/292636075.md)
- [Sumitomo Mitsui Trust Group Inc. Trims Stock Holdings in Biogen Inc. $BIIB](https://longbridge.com/en/news/292406923.md)